المؤلفون: Zama, Daniele, Zanaroli, Andrea, Corbelli, Agnese, Vecchio, Andrea Lo, Bene, Margherita Del, Colombini, Antonella, Compagno, Francesca, Barone, Angelica, Fontanili, Ilaria, D'Amico, Maria Rosaria, Papa, Maria Rosaria, Petris, Maria Grazia, Calore, Elisabetta, Montalto, Shana, Meneghello, Linda, Brescia, Letizia, Mura, Rosamaria, Spina, Milena La, Muggeo, Paola, Rinieri, Simona

المصدر: Journal of Infectious Diseases; 4/15/2024, Vol. 229 Issue 4, p1050-1058, 9p

مصطلحات موضوعية: PEDIATRIC oncology, COMMUNICABLE diseases, HEMATOPOIETIC stem cell transplantation, REPORTING of diseases, SARS-CoV-2

مستخلص: Objective The objective of this study was to assess the clinical impact and outcome of the SARS-CoV-2 infection on children with cancer or those who received a hematopoietic stem cell transplantation. Methods AIEOP (Italian Association of Pediatric Hematology and Oncology) performed a nationwide multicenter observational cohort study, including consecutive patients between April 2020 and November 2022. Results Twenty-five Italian centers participated and 455 patients were enrolled. We reported a significant increasing trend of symptomatic cases over the years, while the number of nonmild infections remained stable. Early infection after oncologic diagnosis (<60 days) and severe neutropenia were identified as independent risk factors for developing moderate, severe, or critical infections. The percentage of patients who were asymptomatic and mildly symptomatic and who stopped chemotherapy reduced over the years of the pandemic. Nine patients died, but no death was attributed to SARS-CoV-2 infection. Conclusions SARS-CoV-2 infection presented a self-limiting benign course in the Italian pediatric oncohematology population during the pandemic, and its main consequence has been the discontinuation of cancer-directed therapies. The rate of patients who were asymptomatic and stopped chemotherapy reduced over the years, suggesting that the continuation of chemotherapy is a feasible option. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Bisogno, Gianni, Provenzi, Massimo, Zama, Daniele, Tondo, Annalisa, Meazza, Cristina, Colombini, Antonella, Galaverna, Federica, Compagno, Francesca, Carraro, Francesca, Santis, Raffaela De, Meneghello, Linda, Baretta, Valentina, Cesaro, Simone

المصدر: Journal of the Pediatric Infectious Diseases Society; Nov2020, Vol. 9 Issue 5, p530-534, 5p

مصطلحات موضوعية: STEM cell transplantation, CANCER chemotherapy, CANCER patients, CRITICAL care medicine, IMMUNOTHERAPY, LONGITUDINAL method, TUMORS in children, SYMPTOMS, TREATMENT effectiveness, LOPINAVIR-ritonavir, COVID-19, HYDROXYCHLOROQUINE, CHILDREN

مصطلحات جغرافية: ITALY

مستخلص: Background Little is known as yet about the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children being treated for cancer. Methods We collected information on the clinical characteristics and outcomes of a cohort of 29 children (16 female and 13 male; median age, 7 years [range, 0–16 years]) diagnosed with SARS-CoV-2 infection while on chemotherapy/immunotherapy (n = 26), or after stem cell transplantation (n = 3) during the peak of the epidemic in Italy. These patients suffered from leukemia (n = 16), lymphoma (n = 3), solid tumors (n = 10), and Langerhans cell histiocytosis (n = 1). Results The course of the disease was mild in all cases, with only 12 children developing symptoms (pneumonia in 3 cases), and none needing intensive care. Fifteen patients were hospitalized, including 7 asymptomatic patients. Nine patients (including 5 with no symptoms) were given hydroxychloroquine, and 3 of them were also given lopinavir/ritonavir. Among the 26 patients on chemotherapy/immunotherapy, the treatment was suspended in 16 cases for a median of 26 days (range, 15–68 days), whereas 8 patients continued their chemotherapy and 2 had minor modifications to their treatment regimen. Conclusions SARS-CoV-2 infection seems to take a milder clinical course in children than in adults with cancer. Specific SARS-CoV-2 treatment seems unnecessary for most children. In light of our findings, and albeit with the necessary caution, we suggest avoiding major changes to planned anticancer treatments in pediatric patients acquiring COVID-19. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of the Pediatric Infectious Diseases Society is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Spahr, Yasmin, Tschudin-Sutter, Sarah, Baettig, Veronika, Compagno, Francesca, Tamm, Michael, Halter, Jörg, Gerull, Sabine, Passweg, Jakob, Hirsch, Hans H, Khanna, Nina

المصدر: Open Forum Infectious Diseases; May2018, Vol. 5 Issue 5, pN.PAG-N.PAG, 1p

مستخلص: Background Paramyxoviruses include respiratory syncytial virus (RSV), parainfluenza virus (PIV), and human metapneumovirus (MPV), which may cause significant respiratory tract infectious disease (RTID) and mortality after allogeneic hematopoietic cell transplantation (HCT). However, clinical data regarding frequency and outcome are scarce. Methods We identified all paramyxovirus RTIDs in allogeneic HCT recipients diagnosed by multiplex polymerase chain reaction between 2010 and 2014. Baseline characteristics of patients, treatment, and outcome of each episode were analyzed; ie, moderate, severe, and very severe immunodeficiency (verySID) according to HCT ≤6 months, T- or B-cell depletion ≤3 months, graft-versus-host disease, neutropenia, lymphopenia, or hypo-gammaglobulinemia. Results One hundred three RTID episodes in 66 patients were identified (PIV 47% [48 of 103], RSV 32% [33 of 103], MPV 21% [22 of 103]). Episodes occurred in 85% (87 of 103) at >100 days post-HCT. Lower RTID accounted for 36% (37 of 103). Thirty-nine percent (40 of 103) of RTID episodes required hospitalization and more frequently affected patients with lower RTID. Six percent progressed from upper to lower RTID. Overall mortality was 6% and did not differ between paramyxoviruses. Sixty-one percent (63 of 103) of episodes occurred in patients with SID, and 20.2% (19 of 63) of episodes occurred in patients with verySID. Oral ribavirin plus intravenous immunoglobulin was administered in 38% (39 of 103) of RTIDs, preferably for RSV or MPV (P ≤.001) and for SID patients (P =.001). Patients with verySID frequently progressed to lower RTID (P =.075), required intensive care unit transfer, and showed higher mortality. Conclusion Paramyxovirus RTID remains a major concern in allogeneic HCT patients fulfilling SID and verySID, emphasizing that efficacious and safe antiviral treatments are urgently needed. [ABSTRACT FROM AUTHOR]

: Copyright of Open Forum Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)